Product Details

Product Information

Mycoten®-Plus vaginal cream contains oil base components. Some of these have been known to  weaken rubber of condoms and diaphragms and make them less effective as a barrier method of Contraception or as a protection. Patients should be advised from sexually transmitted disease including AIDS patients should be advised to use alternative precautions of contraceptives at least five days after using the product. Cross resistance has been demonstrated between Clindamycin and Lincomycin, Erythromycin and Clindamycin. Antagonism has been demonstrated between clindamycin and erythromycin in-vitro. However, very little Clindamycin is absorbed into the blood stream when given vaginally so the likelihood of drug interactions is less. No information is available on concomitant use with other intravaginal products which is not recommended.

WARNINGS/PRECAUTIONS

If local irritation or allergic reaction should occur, the treatment should be discontinued.

Mycoten®-Plus Vaginal Cream/Tablet should not be used during the first trimester of pregnancy unless it is clearly needed because it has not been properly evaluated during the first trimester.

PREGNANCY AND LACTATION

Pregnancy

Clotrimazole has been used in pregnant patients for over a decade without attributable adverse effects.

It is therefore recommended that Clotrimazole should be used in pregnancy only when considered necessary by the clinician.

The frequency of congenital abnormalities was not increased when pregnant women used Clindamycin during the second and third trimesters and Clindamycin vaginal cream is approved for use during the second and third trimesters of pregnancy. However Clindamycin should not be used during the first trimester of pregnancy unless it is clearly needed because it has not been properly evaluated during the first trimester.

During pregnancy, extra care should be taken when using the applicator to prevent the possibility of mechanical trauma.

Lactation

It is not known if Clindamycin is excreted in breast milk following the use of vaginally administered Clindamycin. However, orally and parenterally administered Clindamycin has been reported to appear in breast milk. Therefore, a full assessment of benefit-risk should be made when consideration is given to using vaginal Clindamycin phosphate in a nursing mother.